Industry Experts

Lalit Kumar, Director of Clinical Bioanalytics and Translational Science at Beam Therapeutics, is currently heading implementation of biomarkers strategy in clinical trials to develop cellular therapeutics targeting T cell leukemia and Lymphoma. He brings in 10 years of clinical bioanalytical expertise and leadership in precision medicine which includes clinical assay design and development. Before joining Beam Therapeutics, he was Associate Director of Clinical Pharmacology at CRISPR Therapeutics, leading clinical biomarkers strategies for phase I/II clinical trials for hematology and immuno-oncology pipelines, including CASGEVYTM. As an independent investigator at Harvard medical school, he also worked on human T/B/NK cell primary immunodeficiencies.